MVP feels the luck of the Irish
Medical Developments International (ASX: MVP) announced this week it received final approval from the Health Products Regulatory Authority of the Republic of Ireland to market and sell its inhaled pain-relief product Penthrox. The company said the approval gives MVP’s partner in Ireland and the United Kingdom, Galen, the opportunity to sell Penthrox effective immediately. Shares in MVP jumped following the announcement, and closed up 14.6% for the week. We own MVP in the investment portfolio.
1 stock mentioned
Wilson Asset Management has a track record of making a difference for shareholders and the community for more than 20 years. As the investment manager for eight leading LICs – WAM Capital (ASX: WAM), WAM Leaders (ASX: WLE), WAM Global (ASX: WGB),...